Figures & data
Table 1. Patient demographics and baseline characteristics in the ITT population and Asian subgroup.
Figure 1. Change from baseline for EORTC QLQ-C30 at weeks 12 and 18.
Abbreviations: EORTC, European Organization for Research and Treatment of Cancer; GHS/QoL, global health status/quality of life; ICC, investigator-chosen chemotherapy; ITT, intent-to-treat; LS, least square; n, patents with baseline and at least one post-baseline measurement; QLQ-C30, Quality of Life Questionnaire Core 30.
Figure 2. Change from baseline for QLQ-OES18 scores at weeks 12 and 18.
Abbreviations: ICC, investigator-chosen chemotherapy; ITT, intent-to-treat; LS, least square; n, patients with baseline and at least one post-baseline measurement; QLQ-OES18, Quality-of-Life Questionnaire – Oesophageal Cancer Module.
302PRO_Supplement_13Jan2023.docx
Download MS Word (17.8 KB)Data availability statement
BeiGene voluntarily shares anonymous data on completed studies responsibly and provides qualified scientific and medical researchers access to anonymous data and supporting clinical trial documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeiGene shares data only when permitted by applicable data privacy and security laws and regulations. In addition, data can only be shared when it is feasible to do so without compromising the privacy of study participants. Qualified researchers may submit data requests/research proposals for BeiGene review and consideration through BeiGene’s clinical trial webpage at https://www.beigene.com/our-science-and-medicines/our-clinical-trials/.